New research center focused on brain-body relationship established at MIT

The inextricable link between our brains and our bodies has been gaining increasing recognition among researchers and clinicians over recent years. Studies have shown that the brain-body pathway is bidirectional — meaning that our mental state can influence our physical health and vice versa. But exactly how the two interact is less clear.

A new research center at MIT, funded by a $38 million gift to the McGovern Institute for Brain Research from philanthropist K. Lisa Yang, aims to unlock this mystery by creating and applying novel tools to explore the multidirectional, multilevel interplay between the brain and other body organ systems. This gift expands Yang’s exceptional philanthropic support of human health and basic science research at MIT over the past five years.

“Lisa Yang’s visionary gift enables MIT scientists and engineers to pioneer revolutionary technologies and undertake rigorous investigations into the brain’s complex relationship with other organ systems,” says MIT President L. Rafael Reif.  “Lisa’s tremendous generosity empowers MIT scientists to make pivotal breakthroughs in brain and biomedical research and, collectively, improve human health on a grand scale.”

The K. Lisa Yang Brain-Body Center will be directed by Polina Anikeeva, professor of materials science and engineering and brain and cognitive sciences at MIT and an associate investigator at the McGovern Institute. The center will harness the power of MIT’s collaborative, interdisciplinary life sciences research and engineering community to focus on complex conditions and diseases affecting both the body and brain, with a goal of unearthing knowledge of biological mechanisms that will lead to promising therapeutic options.

“Under Professor Anikeeva’s brilliant leadership, this wellspring of resources will encourage the very best work of MIT faculty, graduate fellows, and research — and ultimately make a real impact on the lives of many,” Reif adds.

microscope image of gut
Mouse small intestine stained to reveal cell nucleii (blue) and peripheral nerve fibers (red).
Image: Polina Anikeeva, Marie Manthey, Kareena Villalobos

Center goals  

Initial projects in the center will focus on four major lines of research:

  • Gut-Brain: Anikeeva’s group will expand a toolbox of new technologies and apply these tools to examine major neurobiological questions about gut-brain pathways and connections in the context of autism spectrum disorders, Parkinson’s disease, and affective disorders.
  • Aging: CRISPR pioneer Feng Zhang, the James and Patricia Poitras Professor of Neuroscience at MIT and investigator at the McGovern Institute, will lead a group in developing molecular tools for precision epigenomic editing and erasing accumulated “errors” of time, injury, or disease in various types of cells and tissues.
  • Pain: The lab of Fan Wang, investigator at the McGovern Institute and professor of brain and cognitive sciences, will design new tools and imaging methods to study autonomic responses, sympathetic-parasympathetic system balance, and brain-autonomic nervous system interactions, including how pain influences these interactions.
  • Acupuncture: Wang will also collaborate with Hilda (“Scooter”) Holcombe, a veterinarian in MIT’s Division of Comparative Medicine, to advance techniques for documenting changes in brain and peripheral tissues induced by acupuncture in mouse models. If successful, these techniques could lay the groundwork for deeper understandings of the mechanisms of acupuncture, specifically how the treatment stimulates the nervous system and restores function.

A key component of the K. Lisa Yang Brain-Body Center will be a focus on educating and training the brightest young minds who aspire to make true breakthroughs for individuals living with complex and often devastating diseases. A portion of center funding will endow the new K. Lisa Yang Brain-Body Fellows Program, which will support four annual fellowships for MIT graduate students and postdocs working to advance understanding of conditions that affect both the body and brain.

Mens sana in corpore sano

“A phrase I remember reading in secondary school has always stuck with me: ‘mens sana in corpore sano’ ‘a healthy mind in a healthy body,’” says Lisa Yang, a former investment banker committed to advocacy for individuals with visible and invisible disabilities. “When we look at how stress, nutrition, pain, immunity, and other complex factors impact our health, we truly see how inextricably linked our brains and bodies are. I am eager to help MIT scientists and engineers decode these links and make real headway in creating therapeutic strategies that result in longer, healthier lives.”

“This center marks a once-in-a-lifetime opportunity for labs like mine to conduct bold and risky studies into the complexities of brain-body connections,” says Anikeeva, who works at the intersection of materials science, electronics, and neurobiology. “The K. Lisa Yang Brain-Body Center will offer a pathbreaking, holistic approach that bridges multiple fields of study. I have no doubt that the center will result in revolutionary strides in our understanding of the inextricable bonds between the brain and the body’s peripheral organ systems, and a bold new way of thinking in how we approach human health overall.”

The craving state

This story originally appeared in the Winter 2022 issue of BrainScan.

***

For people struggling with substance use disorders — and there are about 35 million of them worldwide — treatment options are limited. Even among those who seek help, relapse is common. In the United States, an epidemic of opioid addiction has been declared a public health emergency.

A 2019 survey found that 1.6 million people nationwide had an opioid use disorder, and the crisis has surged since the start of the COVID-19 pandemic. The Centers for Disease Control and Prevention estimates that more than 100,000 people died of drug overdose between April 2020 and April 2021 — nearly 30 percent more overdose deaths than occurred during the same period the previous year.

In the United States, an epidemic of opioid addiction has been declared a public health emergency.

A deeper understanding of what addiction does to the brain and body is urgently needed to pave the way to interventions that reliably release affected individuals from its grip. At the McGovern Institute, researchers are turning their attention to addiction’s driving force: the deep, recurring craving that makes people prioritize drug use over all other wants and needs.

McGovern Institute co-founder, Lore Harp McGovern.

“When you are in that state, then it seems nothing else matters,” says McGovern Investigator Fan Wang. “At that moment, you can discard everything: your relationship, your house, your job, everything. You only want the drug.”

With a new addiction initiative catalyzed by generous gifts from Institute co-founder Lore Harp McGovern and others, McGovern scientists with diverse expertise have come together to begin clarifying the neurobiology that underlies the craving state. They plan to dissect the neural transformations associated with craving at every level — from the drug-induced chemical changes that alter neuronal connections and activity to how these modifications impact signaling brain-wide. Ultimately, the McGovern team hopes not just to understand the craving state, but to find a way to relieve it — for good.

“If we can understand the craving state and correct it, or at least relieve a little bit of the pressure,” explains Wang, who will help lead the addiction initiative, “then maybe we can at least give people a chance to use their top-down control to not take the drug.”

The craving cycle

For individuals suffering from substance use disorders, craving fuels a cyclical pattern of escalating drug use. Following the euphoria induced by a drug like heroin or cocaine, depression sets in, accompanied by a drug craving motivated by the desire to relieve that suffering. And as addiction progresses, the peaks and valleys of this cycle dip lower: the pleasant feelings evoked by the drug become weaker, while the negative effects a person experiences in its absence worsen. The craving remains, and increasing use of the drug are required to relieve it.

By the time addiction sets in, the brain has been altered in ways that go beyond a drug’s immediate effects on neural signaling.

These insidious changes leave individuals susceptible to craving — and the vulnerable state endures. Long after the physical effects of withdrawal have subsided, people with substance use disorders can find their craving returns, triggered by exposure to a small amount of the drug, physical or social cues associated with previous drug use, or stress. So researchers will need to determine not only how different parts of the brain interact with one another during craving and how individual cells and the molecules within them are affected by the craving state — but also how things change as addiction develops and progresses.

Circuits, chemistry and connectivity

One clear starting point is the circuitry the brain uses to control motivation. Thanks in part to decades of research in the lab of McGovern Investigator Ann Graybiel, neuroscientists know a great deal about how these circuits learn which actions lead to pleasure and which lead to pain, and how they use that information to establish habits and evaluate the costs and benefits of complex decisions.

Graybiel’s work has shown that drugs of abuse strongly activate dopamine-responsive neurons in a part of the brain called the striatum, whose signals promote habit formation. By increasing the amount of dopamine that neurons release, these drugs motivate users to prioritize repeated drug use over other kinds of rewards, and to choose the drug in spite of pain or other negative effects. Her group continues to investigate the naturally occurring molecules that control these circuits, as well as how they are hijacked by drugs of abuse.

Distribution of opioid receptors targeted by morphine (shown in blue) in two regions in the dorsal striatum and nucleus accumbens of the mouse brain. Image: Ann Graybiel

In Fan Wang’s lab, work investigating the neural circuits that mediate the perception of physical pain has led her team to question the role of emotional pain in craving. As they investigated the source of pain sensations in the brain, they identified neurons in an emotion-regulating center called the central amygdala that appear to suppress physical pain in animals. Now, Wang wants to know whether it might be possible to modulate neurons involved in emotional pain to ameliorate the negative state that provokes drug craving.

These animal studies will be key to identifying the cellular and molecular changes that set the brain up for recurring cravings. And as McGovern scientists begin to investigate what happens in the brains of rodents that have been trained to self-administer addictive drugs like fentanyl or cocaine, they expect to encounter tremendous complexity.

McGovern Associate Investigator Polina Anikeeva, whose lab has pioneered new technologies that will help the team investigate the full spectrum of changes that underlie craving, says it will be important to consider impacts on the brain’s chemistry, firing patterns, and connectivity. To that end, multifunctional research probes developed in her lab will be critical to monitoring and manipulating neural circuits in animal models.

Imaging technology developed by investigator Ed Boyden will also enable nanoscale protein visualization brain-wide. An important goal will be to identify a neural signature of the craving state. With such a signal, researchers can begin to explore how to shut off that craving — possibly by directly modulating neural signaling.

Targeted treatments

“One of the reasons to study craving is because it’s a natural treatment point,” says McGovern Associate Investigator Alan Jasanoff. “And the dominant kind of approaches that people in our team think about are approaches that relate to neural circuits — to the specific connections between brain regions and how those could be changed.” The hope, he explains, is that it might be possible to identify a brain region whose activity is disrupted during the craving state, then use clinical brain stimulation methods to restore normal signaling — within that region, as well as in other connected parts of the brain.

To identify the right targets for such a treatment, it will be crucial to understand how the biology uncovered in laboratory animals reflects what’s happens in people with substance use disorders. Functional imaging in John Gabrieli’s lab can help bridge the gap between clinical and animal research by revealing patterns of brain activity associated with the craving state in both humans and rodents. A new technique developed in Jasanoff’s lab makes it possible to focus on the activity between specific regions of an animal’s brain. “By doing that, we hope to build up integrated models of how information passes around the brain in craving states, and of course also in control states where we’re not experiencing craving,” he explains.

In delving into the biology of the craving state, McGovern scientists are embarking on largely unexplored territory — and they do so with both optimism and urgency. “It’s hard to not appreciate just the size of the problem, and just how devastating addiction is,” says Anikeeva. “At this point, it just seems almost irresponsible to not work on it, especially when we do have the tools and we are interested in the general brain regions that are important for that problem. I would say that there’s almost a civic duty.”

MIT Future Founders Initiative announces prize competition to promote female entrepreneurs in biotech

In a fitting sequel to its entrepreneurship “boot camp” educational lecture series last fall, the MIT Future Founders Initiative has announced the MIT Future Founders Prize Competition, supported by Northpond Ventures, and named the MIT faculty cohort that will participate in this year’s competition. The Future Founders Initiative was established in 2020 to promote female entrepreneurship in biotech.

Despite increasing representation at MIT, female science and engineering faculty found biotech startups at a disproportionately low rate compared with their male colleagues, according to research led by the initiative’s founders, MIT Professor Sangeeta Bhatia, MIT Professor and President Emerita Susan Hockfield, and MIT Amgen Professor of Biology Emerita Nancy Hopkins. In addition to highlighting systemic gender imbalances in the biotech pipeline, the initiative’s founders emphasize that the dearth of female biotech entrepreneurs represents lost opportunities for society as a whole — a bottleneck in the proliferation of publicly accessible medical and technological innovation.

“A very common myth is that representation of women in the pipeline is getting better with time … We can now look at the data … and simply say, ‘that’s not true’,” said Bhatia, who is the John and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, and a member of MIT’s Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science, in an interview for the March/April 2021 MIT Faculty Newsletter. “We need new solutions. This isn’t just about waiting and being optimistic.”

Inspired by generous funding from Northpond Labs, the research and development-focused affiliate of Northpond Ventures, and by the success of other MIT prize incentive competitions such as the Climate Tech and Energy Prize, the Future Founders Initiative Prize Competition will be structured as a learning cohort in which participants will be supported in commercializing their existing inventions with instruction in market assessments, fundraising, and business capitalization, as well as other programming. The program, which is being run as a partnership between the MIT School of Engineering and the Martin Trust Center for MIT Entrepreneurship, provides hands-on opportunities to learn from industry leaders about their experiences, ranging from licensing technology to creating early startup companies. Bhatia and Kit Hickey, an entrepreneur-in-residence at the Martin Trust Center and senior lecturer at the MIT Sloan School of Management, are co-directors of the program.

“The competition is an extraordinary effort to increase the number of female faculty who translate their research and ideas into real-world applications through entrepreneurship,” says Anantha Chandrakasan, dean of the MIT School of Engineering and Vannevar Bush Professor of Electrical Engineering and Computer Science. “Our hope is that this likewise serves as an opportunity for participants to gain exposure and experience to the many ways in which they could achieve commercial impact through their research.”

At the end of the program, the cohort members will pitch their ideas to a selection committee composed of MIT faculty, biotech founders, and venture capitalists. The grand prize winner will receive $250,000 in discretionary funds, and two runners-up will receive $100,000. The winners will be announced at a showcase event, at which the entire cohort will present their work. All participants will also receive a $10,000 stipend for participating in the competition.

“The biggest payoff is not identifying the winner of the competition,” says Bhatia. “Really, what we are doing is creating a cohort … and then, at the end, we want to create a lot of visibility for these women and make them ‘top of mind’ in the community.”

The Selection Committee members for the MIT Future Founders Prize Competition are:

  • Bill Aulet, professor of the practice in the MIT Sloan School of Management and managing director of the Martin Trust Center for MIT Entrepreneurship
  • Sangeeta Bhatia, the John and Dorothy Wilson Professor of Electrical Engineering and Computer Science at MIT; a member of MIT’s Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science; and founder of Hepregen, Glympse Bio, and Satellite Bio
  • Kit Hickey, senior lecturer in the MIT Sloan School of Management and entrepreneur-in-residence at the Martin Trust Center
  • Susan Hockfield, MIT president emerita and professor of neuroscience
  • Andrea Jackson, director at Northpond Ventures
  • Harvey Lodish, professor of biology and biomedical engineering at MIT and founder of Genzyme, Millennium, and Rubius
  • Fiona Murray, associate dean for innovation and inclusion in the MIT Sloan School of Management; the William Porter Professor of Entrepreneurship; co-director of the MIT Innovation Initiative; and faculty director of the MIT Legatum Center
  • Amy Schulman, founding CEO of Lyndra Therapeutics and partner at Polaris Partners
  • Nandita Shangari, managing director at Novartis Venture Fund

“As an investment firm dedicated to supporting entrepreneurs, we are acutely aware of the limited number of companies founded and led by women in academia. We believe humanity should be benefiting from brilliant ideas and scientific breakthroughs from women in science, which could address many of the world’s most pressing problems. Together with MIT, we are providing an opportunity for women faculty members to enhance their visibility and gain access to the venture capital ecosystem,” says Andrea Jackson, director at Northpond Ventures.

“This first cohort is representative of the unrealized opportunity this program is designed to capture. While it will take a while to build a robust community of connections and role models, I am pleased and confident this program will make entrepreneurship more accessible and inclusive to our community, which will greatly benefit society,” says Susan Hockfield, MIT president emerita.

The MIT Future Founders Prize Competition cohort members were selected from schools across MIT, including the School of Science, the School of Engineering, and Media Lab within the School of Architecture and Planning. They are:

Polina Anikeeva is professor of materials science and engineering and brain and cognitive sciences, an associate member of the McGovern Institute for Brain Research, and the associate director of the Research Laboratory of Electronics. She is particularly interested in advancing the possibility of future neuroprosthetics, through biologically-informed materials synthesis, modeling, and device fabrication. Anikeeva earned her BS in biophysics from St. Petersburg State Polytechnic University and her PhD in materials science and engineering from MIT.

Natalie Artzi is principal research scientist in the Institute of Medical Engineering and Science and an assistant professor in the department of medicine at Brigham and Women’s Hospital. Through the development of smart materials and medical devices, her research seeks to “personalize” medical interventions based on the specific presentation of diseased tissue in a given patient. She earned both her BS and PhD in chemical engineering from the Technion-Israel Institute of Technology.

Laurie A. Boyer is professor of biology and biological engineering in the Department of Biology. By studying how diverse molecular programs cross-talk to regulate the developing heart, she seeks to develop new therapies that can help repair cardiac tissue. She earned her BS in biomedical science from Framingham State University and her PhD from the University of Massachusetts Medical School.

Tal Cohen is associate professor in the departments of Civil and Environmental Engineering and Mechanical Engineering. She wields her understanding of how materials behave when they are pushed to their extremes to tackle engineering challenges in medicine and industry. She earned her BS, MS, and PhD in aerospace engineering from the Technion-Israel Institute of Technology.

Canan Dagdeviren is assistant professor of media arts and sciences and the LG Career Development Professor of Media Arts and Sciences. Her research focus is on creating new sensing, energy harvesting, and actuation devices that can be stretched, wrapped, folded, twisted, and implanted onto the human body while maintaining optimal performance. She earned her BS in physics engineering from Hacettepe University, her MS in materials science and engineering from Sabanci University, and her PhD in materials science and engineering from the University of Illinois at Urbana-Champaign.

Ariel Furst is the Raymond (1921) & Helen St. Laurent Career Development Professor in the Department of Chemical Engineering. Her research addresses challenges in global health and sustainability, utilizing electrochemical methods and biomaterials engineering. She is particularly interested in new technologies that detect and treat disease. Furst earned her BS in chemistry at the University of Chicago and her PhD at Caltech.

Kristin Knouse is assistant professor in the Department of Biology and the Koch Institute for Integrative Cancer Research. She develops tools to investigate the molecular regulation of organ injury and regeneration directly within a living organism with the goal of uncovering novel therapeutic avenues for diverse diseases. She earned her BS in biology from Duke University, her PhD and MD through the Harvard and MIT MD-PhD program.

Elly Nedivi is the William R. (1964) & Linda R. Young Professor of Neuroscience at the Picower Institute for Learning and Memory with joint appointments in the departments of Brain and Cognitive Sciences and Biology. Through her research of neurons, genes, and proteins, Nedivi focuses on elucidating the cellular mechanisms that control plasticity in both the developing and adult brain. She earned her BS in biology from Hebrew University and her PhD in neuroscience from Stanford University.

Ellen Roche is associate professor in the Department of Mechanical Engineering and Institute of Medical Engineering and Science, and the W.M. Keck Career Development Professor in Biomedical Engineering. Borrowing principles and design forms she observes in nature, Roche works to develop implantable therapeutic devices that assist cardiac and other biological function. She earned her bachelor’s degree in biomedical engineering from the National University of Ireland at Galway, her MS in bioengineering from Trinity College Dublin, and her PhD from Harvard University.

Seven from MIT receive National Institutes of Health awards

On Oct. 5, the National Institutes of Health announced the names of 106 scientists who have been awarded grants through the High-Risk, High-Reward Research program to advance highly innovative biomedical and behavioral research. Seven of the recipients are MIT faculty members.

The High-Risk, High-Reward Research program catalyzes scientific discovery by supporting research proposals that, due to their inherent risk, may struggle in the traditional peer-review process despite their transformative potential. Program applicants are encouraged to pursue trailblazing ideas in any area of research relevant to the NIH’s mission to advance knowledge and enhance health.

“The science put forward by this cohort is exceptionally novel and creative and is sure to push at the boundaries of what is known,” says NIH Director Francis S. Collins. “These visionary investigators come from a wide breadth of career stages and show that groundbreaking science can happen at any career level given the right opportunity.”

New innovators

Four MIT researchers received New Innovator Awards, which recognize “unusually innovative research from early career investigators.” They are:

  • Pulin Li is a member at the Whitehead Institute for Biomedical Research and an assistant professor in the Department of Biology. Li combines approaches from synthetic biology, developmental biology, biophysics and systems biology to quantitatively understand the genetic circuits underlying cell-cell communication that creates multicellular behaviors.
  • Seychelle Vos, the Robert A. Swanson (1969) Career Development Professor of Life Sciences in the Department of Biology, studies the interplay of gene expression and genome organization. Her work focuses on understanding how large molecular machineries involved in genome organization and gene transcription regulate each others’ function to ultimately determine cell fate and identity.
  • Xiao Wang, the Thomas D. and Virginia Cabot Assistant Professor of Chemistry and a member of the Broad Institute of MIT and Harvard, aims to develop high-resolution and highly-multiplexed molecular imaging methods across multiple scales toward understanding the physical and chemical basis of brain wiring and function.
  • Alison Wendlandt is a Cecil and Ida Green Career Development Assistant Professor of Chemistry. Wendlandt focuses on the development of selective, catalytic reactions using the tools of organic and organometallic synthesis and physical organic chemistry. Mechanistic study plays a central role in the development of these new transformations.

Transformative researchers

Two MIT researchers have received Transformative Research Awards, which “promote cross-cutting, interdisciplinary approaches that could potentially create or challenge existing paradigms.” The recipients are:

  • Manolis Kellis is a professor of computer science at MIT in the area of computational biology, an associate member of the Broad Institute, and a principal investigator with MIT’s Computer Science and Artificial Intelligence Laboratory. He aims to further our understanding of the human genome by computational integration of large-scale functional and comparative genomics datasets.
  • Myriam Heiman is the Latham Family Career Development Associate Professor of Neuroscience in the Department of Brain and Cognitive Sciences and an investigator in the Picower Institute for Learning and Memory. Heiman studies the selective vulnerability and pathophysiology seen in two neurodegenerative diseases of the basal ganglia, Huntington’s disease, and Parkinson’s disease.

Together, Heiman, Kellis and colleagues will launch a five-year investigation to pinpoint what may be going wrong in specific brain cells and to help identify new treatment approaches for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with motor neuron disease (FTLD/MND). The project will bring together four labs, including Heiman and Kellis’ labs at MIT, to apply innovative techniques ranging from computational, genomic, and epigenomic analyses of cells from a rich sample of central nervous system tissue, to precision genetic engineering of stem cells and animal models.

Pioneering researchers

  • Polina Anikeeva received a Pioneer Award, which “challenges investigators at all career levels to pursue new research directions and develop groundbreaking, high-impact approaches to a broad area of biomedical, behavioral, or social science.” Anikeeva is an MIT professor of materials science and engineering, a professor of brain and cognitive sciences, and a McGovern Institute for Brain Research associate investigator. She has established a research program that uniquely combines materials synthesis, device fabrication, neurophysiology, and animal models of behavior. Her group carries out projects that understand, invent, and design materials from the level of atoms to functional devices with applications in fundamental neuroscience.

The program is supported by the NIH Common Fund, which oversees programs that pursue major opportunities and gaps throughout the research enterprise that are of great importance to NIH and require collaboration across the agency to succeed. It issues four awards each year: the Pioneer Award, the New Innovator Award, the Transformative Research Award, and the Early Independence Award.

This year, NIH issued 10 Pioneer awards, 64 New Innovator awards, 19 Transformative Research awards (10 general, four ALS-related, and five Covid-19-related), and 13 Early Independence awards for 2021. Funding for the awards comes from the NIH Common Fund, the National Institute of General Medical Sciences, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke.

Squishy, stealthy neural probes

Slender probes equipped with electrodes, optical channels, and other tools are widely used by neuroscientists to monitor and manipulate brain activity in animal studies. Now, scientists at MIT have devised a way to make these usually rigid devices become as soft and pliable as their surroundings when they are implanted in the brain. Their new multifunctional devices are less intrusive than traditional neuroscience probes and remain functional for months after implantation, enabling long-term studies of neural circuits in animal models.

Researchers led by McGovern Institute scientist Polina Anikeeva built the new devices by embedding their functional components in a water-absorbing hydrogel. Each device begins as stiff probe able to penetrate brain tissue. But once it is in place, the hydrogel absorbs water and the device transforms.

“When it’s dry, it’s completely rigid. Its mechanics are dominated by mechanics of the polymers and metals that went into it,” explains Anikeeva, who is also an associate professor in the Departments of Materials Science and Engineering and Brain and Cognitive Sciences. “When it’s fully hydrated, it has the [mechanical] properties of the brain.”

Anikeeva and colleagues reported on the new devices in the June 8 issue of Nature Communications.

Stealthy probes

Neural probes made out of metal or hard plastics have been invaluable in neuroscience research, allowing scientists to sense electrical activity within the brain, supply drugs to specific locations, or deliver neuron-activating pulses of light.

In 2015, Anikeeva and her group developed multifunctional probes, which are equipped with the tools to do all of these things. Although these polymer based devices were more biocompatible than metals and semiconductors, which can cut like tiny knives through the soft, jiggly tissue of the brain, their mechanics were still orders of magnitude away from those of neural tissue. Most neural probes can be used for a few weeks, until scar tissue forms around them and interferes with their function.

“For some experiments, this may not matter,” Anikeeva says. “But for other experiments, it does. If, for example, you’re interested in how a neuron evolves over the course of long-term behavior, or aging, or development, it’s important to keep track of the same tissue or the same cells. And that was challenging [with rigid probes].”

To enable longer experiments, Anikeeva’s team began to think about making multifunctional probes out of a material that is more compatible with the brain. “We wanted to create a device that would be stealthy, so the brain wouldn’t know that it’s there,” she says. To be useful, the device would still need some amount of hard material. But electrodes, microfluidic chambers, and optical channels can be tiny—just a fraction of the width of a human hair. “Even if they’re made out of polymer or soft metal, if you make them that small, they become sufficiently soft that they will be able to move with the brain and not cause damage,” Anikeeva says. It is the polymer matrix that surrounds these functional components that gives neural probes their shape and rigidity, which despite causing problems once inside the brain, is essential for implantation.

 

Seongjun Park, a graduate student in Anikeeva’s group, and Hyunwoo Yuk, another MIT graduate student who had been working with hydrogels in Xuanhe Zhao’s mechanical engineering lab, discussed the problem and proposed a probe that took advantage of that material. Because of hydrogels’ tunable nature, they could be used to build a device that was both stealthily squishy and piercingly rigid. By fine-tuning the chemistry, the team could ensure that after the device was implanted, its hydrogel would absorb just enough water to closely match the mechanics of the brain.

Hydrogel glue

Other researchers had previously developed neural probes wrapped in a hydrogel covering, but Anikeeva’s team wanted the hydrogel to be the bulk of the device. They would use the swellable material to bundle together the functional elements and fill the space between them.

To do so, they assembled the fibers that would give their device its desired function—an electrode array fiber for sensing neural activity, an optical fiber for delivering light to manipulate signaling, and a fluidic fiber for delivering drugs and genes—and chemically treated them so that they would adhere directly to the components of a hydrogel.

 

They then dipped the treated fibers into a solution of a hydrogel-forming compound called alginate. By exposing the solution to light, they triggered the alginate to polymerize, ultimately creating a thin strand of the hydrogel with the functional fibers embedded within it.

When it is first pulled out of the solution, Anikeeva says, the hydrogel-based device is like a wet noodle, with its components moving freely within it like the bendable bristles of a wet paintbrush. As the hydrogel dries, the fibers become firmly affixed to one another and the entire device stiffens—much like a drying paintbrush.

Long-term tracking

To test the devices, Anikeeva’s team implanted them into mice, targeting anxiety circuits deep within the brain. They behaved exactly as they had hoped—easily penetrating into the tissue, then returning to their “wet noodle” state and remaining in place without triggering a foreign body response in the brain. After more than six months of recording neural activity, the probes remained fully functional.

Anikeeva says her team’s squishy new probes are the first multifunctional neural devices to remain effective in living animals for this prolonged period. The improved longevity of the devices compared to their predecessors means researchers will be able to use them to track and manipulate neuronal behavior during long-term processes such as learning, disease progression, and aging.

The team is already working on the next-generation of hydrogel probes, which will further take advantage of the material’s unique properties to control the release of drugs or other compounds within the brain and improve the devices’ biocompatibility. And with a simplified fabrication process in development, Anikeeva says it may soon be possible for neuroscientists to manufacture the stealthy probes in their own labs.

Controlling drug activity with light

Hormones and nutrients bind to receptors on cell surfaces by a lock-and-key mechanism that triggers intracellular events linked to that specific receptor. Drugs that mimic natural molecules are widely used to control these intracellular signaling mechanisms for therapy and in research.

In a new publication, a team led by McGovern Institute Associate Investigator Polina Anikeeva and Oregon Health & Science University Research Assistant Professor James Frank introduce a microfiber technology to deliver and activate a drug that can be induced to bind its receptor by exposure to light.

“A significant barrier in applying light-controllable drugs to modulate neural circuits in living animals is the lack of hardware which enables simultaneous delivery of both light and drugs to the target brain area,” says Frank, who was previously a postdoctoral associate in Anikeeva’s Bioelectronics group at MIT. “Our work offers an integrated approach for on-demand delivery of light and drugs through a single fiber.”

These devices were used to deliver a “photoswitchable” drug deep into the brain. So-called “photoswitches” are light-sensitive molecules that can be attached to drugs to switch their activity on or off with a flash of light ­– the use of these drugs is called photopharmacology. In the new study, photopharmacology is used to control neuronal activity and behavior in mice.

Creating miniaturized devices from macroscale templates

The lightweight device features two microfluidic channel and an optical waveguide, and can easily be carried by the animal during behavior

To use light to control drug activity, light and drugs must be delivered simultaneously to the targeted cells. This is a major challenge when the target is deep in the body, but Anikeeva’s Bioelectronics group is uniquely equipped to deal with this challenge.  Marc-Joseph (MJ) Antonini, a PhD student in Anikeeva’s Bioelectronics lab and co-first author of the study, specializes in the fabrication of biocompatible multifunctional fibers that house microfluidic channels and waveguides to deliver liquids and transmit light.

The multifunctional fibers used in this study contain a fluidic channel and an optical waveguide and are comprised of many layers of different materials that are fused together to provide flexibility and strength. The original form of the fiber is constructed at a macroscale and then heated and pulled (a process called thermal drawing) to become longer, but nearly 70X smaller in diameter. By this method, 100’s of meters of miniaturized fiber can be created from the original template at a cross-sectional scale of micrometers that minimizes tissue damage.

The device used in this study had an implantable fiber bundle of 480µm × 380µm and weighed only 0.8 g, small enough that a mouse can easily carry it on its head for many weeks.

Synthesis of a new photoswitchable drug

To demonstrate effectiveness of their device for simultaneous delivery of liquids and light, the Anikeeva lab teamed up with Dirk Trauner (Frank’s former PhD advisor) and David Konrad,  pharmacologists who synthesized photoswitchable drugs.

They had previously modified a photoswitchable analog of capsaicin, a molecule found in hot peppers that binds to the TRPV1 receptor on sensory neurons and controls the sensation of heat. This modification allowed the capsaicin analog to be activated by 560 nm wave-length of light (visible green) that is not damaging to tissue compared to the original version of the drug that required ultraviolet light. By adding both the TRPV1 receptor and the new photoswitchable capsaicin analog to neurons, they could be artificially activated with green light.

This new photopharmacology system had been shown by Frank, Konrad and their colleagues to work in cells cultured in a dish, but had never been shown to work in freely-moving animals.

Controlling behavior by photopharmacology

To test whether their system could activate neurons in the brain, Frank and Antonini tested it in mice. They asked whether adding the photoswitchable drug and its receptor to reward-mediating neurons in the mouse brain causes mice to prefer a chamber in which they receive light stimulation.

The multifunctional fiber-inspired neural implant was implanted into a phantom brain (left), and successfully delivered light and a blue dye (right).

The miniaturized multifunctional fiber developed by the team was implanted in the mouse brain’s ventral tegmental area, a deep region rich in dopamine neurons that controls reward-seeking behavior. Through the fluidic channel in the device, the researchers delivered a virus that drives expression of the TRPV1 receptor in the neurons under study.  Several weeks later, the device was then used to deliver both light and the photoswitchable capsaicin analog directly to the same neurons. To control for the specificity of their system, they also tested the effects of delivering a virus that does not express the TRPV1 receptor, and the effects of delivering a wavelength of light that does not switch on the drug.

They found that mice showed a preference only for the chamber where they had previously received all three components required for the photopharmacology to function: the receptor-expressing virus, the photoswitchable receptor ligand and the green light that activates the drug. These results demonstrate the efficacy of this system to control the time and place within the body that a drug is active.

“Using these fibers to enable photopharmacology in vivo is a great example of how our multifunctional platform can be leveraged to improve and expand how we can interact with the brain,” says Antonini. “This combination of technologies allows us to achieve the temporal and spatial resolution of light stimulation with the chemical specificity of drug injection in freely moving animals.”

Therapeutic drugs that are taken orally or by injection often cause unwanted side-effects because they act continuously and throughout the whole body. Many unwanted side effects could be eliminated by targeting a drug to a specific body tissue and activating it only as needed. The new technology described by Anikeeva and colleagues is one step toward this ultimate goal.

“Our next goal is to use these neural implants to deliver other photoswitchable drugs to target receptors which are naturally expressed within these circuits,” says Frank, whose new lab in the Vollum Institute at OHSU is synthesizing new light-controllable molecules. “The hardware presented in this study will be widely applicable for controlling circuits throughout the brain, enabling neuroscientists to manipulate them with enhanced precision.”

New molecular therapeutics center established at MIT’s McGovern Institute

More than one million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at MIT’s McGovern Institute aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan ’75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is President and CEO of Broadcom, a global technology infrastructure company. This latest gift brings Yang and Tan’s total philanthropy to MIT to more than $72 million.

Lisa Yang (center) and MIT alumnus Hock Tan ’75 with their daughter Eva (far left) pictured at the opening of the Hock E. Tan and K. Lisa Yang Center for Autism Research in 2017. Photo: Justin Knight

“In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact,” says MIT President L. Rafael Reif. “Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.”

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

“Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds,” says Robert Desimone, McGovern Institute Director and Doris and Don Berkey Professor of Neuroscience at MIT. “I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.”

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain–the highest proportion of genes expressed in any part of the body.

Variations in genetic code have been linked to many complex brain disorders, including depression and Parkinson’s. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by Associate Professor of Materials Science and Engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

“My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MIT’s McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism and epilepsy are just around the corner,” says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yang’s daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

“We want to build a strong pipeline for tomorrow’s scientists and neuroengineers,” explains Hock Tan. “We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.”

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

“We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease,” says Yang.

 

A mechanical way to stimulate neurons

In addition to responding to electrical and chemical stimuli, many of the body’s neural cells can also respond to mechanical effects, such as pressure or vibration. But these responses have been more difficult for researchers to study, because there has been no easily controllable method for inducing such mechanical stimulation of the cells. Now, researchers at MIT and elsewhere have found a new method for doing just that.

The finding might offer a step toward new kinds of therapeutic treatments, similar to electrically based neurostimulation that has been used to treat Parkinson’s disease and other conditions. Unlike those systems, which require an external wire connection, the new system would be completely contact-free after an initial injection of particles, and could be reactivated at will through an externally applied magnetic field.

The finding is reported in the journal ACS Nano, in a paper by former MIT postdoc Danijela Gregurec, Alexander Senko PhD ’19, Associate Professor Polina Anikeeva, and nine others at MIT, at Boston’s Brigham and Women’s Hospital, and in Spain.

The new method opens a new pathway for the stimulation of nerve cells within the body, which has so far almost entirely relied on either chemical pathways, through the use of pharmaceuticals, or on electrical pathways, which require invasive wires to deliver voltage into the body. This mechanical stimulation, which activates entirely different signaling pathways within the neurons themselves, could provide a significant area of study, the researchers say.

“An interesting thing about the nervous system is that neurons can actually detect forces,” Senko says. “That’s how your sense of touch works, and also your sense of hearing and balance.” The team targeted a particular group of neurons within a structure known as the dorsal root ganglion, which forms an interface between the central and peripheral nervous systems, because these cells are particularly sensitive to mechanical forces.

The applications of the technique could be similar to those being developed in the field of bioelectronic medicines, Senko says, but those require electrodes that are typically much bigger and stiffer than the neurons being stimulated, limiting their precision and sometimes damaging cells.

The key to the new process was developing minuscule discs with an unusual magnetic property, which can cause them to start fluttering when subjected to a certain kind of varying magnetic field. Though the particles themselves are only 100 or so nanometers across, roughly a hundredth of the size of the neurons they are trying to stimulate, they can be made and injected in great quantities, so that collectively their effect is strong enough to activate the cell’s pressure receptors. “We made nanoparticles that actually produce forces that cells can detect and respond to,” Senko says.

Anikeeva says that conventional magnetic nanoparticles would have required impractically large magnetic fields to be activated, so finding materials that could provide sufficient force with just moderate magnetic activation was “a very hard problem.” The solution proved to be a new kind of magnetic nanodiscs.

These discs, which are hundreds of nanometers in diameter, contain a vortex configuration of atomic spins when there are no external magnetic fields applied. This makes the particles behave as if they were not magnetic at all, making them exceptionally stable in solutions. When these discs are subjected to a very weak varying magnetic field of a few millitesla, with a low frequency of just several hertz, they switch to a state where the internal spins are all aligned in the disc plane. This allows these nanodiscs to act as levers — wiggling up and down with the direction of the field.

Anikeeva, who is an associate professor in the departments of Materials Science and Engineering and Brain and Cognitive Sciences, says this work combines several disciplines, including new chemistry that led to development of these nanodiscs, along with electromagnetic effects and work on the biology of neurostimulation.

The team first considered using particles of a magnetic metal alloy that could provide the necessary forces, but these were not biocompatible materials, and they were prohibitively expensive. The researchers found a way to use particles made from hematite, a benign iron oxide, which can form the required disc shapes. The hematite was then converted into magnetite, which has the magnetic properties they needed and is known to be benign in the body. This chemical transformation from hematite to magnetite dramatically turns a blood-red tube of particles to jet black.

“We had to confirm that these particles indeed supported this really unusual spin state, this vortex,” Gregurec says. They first tried out the newly developed nanoparticles and proved, using holographic imaging systems provided by colleagues in Spain, that the particles really did react as expected, providing the necessary forces to elicit responses from neurons. The results came in late December and “everyone thought that was a Christmas present,” Anikeeva recalls, “when we got our first holograms, and we could really see that what we have theoretically predicted and chemically suspected actually was physically true.”

The work is still in its infancy, she says. “This is a very first demonstration that it is possible to use these particles to transduce large forces to membranes of neurons in order to stimulate them.”

She adds “that opens an entire field of possibilities. … This means that anywhere in the nervous system where cells are sensitive to mechanical forces, and that’s essentially any organ, we can now modulate the function of that organ.” That brings science a step closer, she says, to the goal of bioelectronic medicine that can provide stimulation at the level of individual organs or parts of the body, without the need for drugs or electrodes.

The work was supported by the U.S. Defense Advanced Research Projects Agency, the National Institute of Mental Health, the Department of Defense, the Air Force Office of Scientific Research, and the National Defense Science and Engineering Graduate Fellowship.

Full paper at ACS Nano

Producing a gaseous messenger molecule inside the body, on demand

Nitric oxide is an important signaling molecule in the body, with a role in building nervous system connections that contribute to learning and memory. It also functions as a messenger in the cardiovascular and immune systems.

But it has been difficult for researchers to study exactly what its role is in these systems and how it functions. Because it is a gas, there has been no practical way to direct it to specific individual cells in order to observe its effects. Now, a team of scientists and engineers at MIT and elsewhere has found a way of generating the gas at precisely targeted locations inside the body, potentially opening new lines of research on this essential molecule’s effects.

The findings are reported today in the journal Nature Nanotechnology, in a paper by MIT professors Polina Anikeeva, Karthish Manthiram, and Yoel Fink; graduate student Jimin Park; postdoc Kyoungsuk Jin; and 10 others at MIT and in Taiwan, Japan, and Israel.

“It’s a very important compound,” says Anikeeva, who is also an Investigator at the McGovern Institute. But figuring out the relationships between the delivery of nitric oxide to particular cells and synapses, and the resulting higher-level effects on the learning process has been difficult. So far, most studies have resorted to looking at systemic effects, by knocking out genes responsible for the production of enzymes the body uses to produce nitric oxide where it’s needed as a messenger.

But that approach, she says, is “very brute force. This is a hammer to the system because you’re knocking it out not just from one specific region, let’s say in the brain, but you essentially knock it out from the entire organism, and this can have other side effects.”

Others have tried introducing compounds into the body that release nitric oxide as they decompose, which can produce somewhat more localized effects, but these still spread out, and it is a very slow and uncontrolled process.

The team’s solution uses an electric voltage to drive the reaction that produces nitric oxide. This is similar to what is happening on a much larger scale with some industrial electrochemical production processes, which are relatively modular and controllable, enabling local and on-demand chemical synthesis. “We’ve taken that concept and said, you know what? You can be so local and so modular with an electrochemical process that you can even do this at the level of the cell,” Manthiram says. “And I think what’s even more exciting about this is that if you use electric potential, you have the ability to start production and stop production in a heartbeat.”

The team’s key achievement was finding a way for this kind of electrochemically controlled reaction to be operated efficiently and selectively at the nanoscale. That required finding a suitable catalyst material that could generate nitric oxide from a benign precursor material. They found that nitrite offered a promising precursor for electrochemical nitric oxide generation.

“We came up with the idea of making a tailored nanoparticle to catalyze the reaction,” Jin says. They found that the enzymes that catalyze nitric oxide generation in nature contain iron-sulfur centers. Drawing inspiration from these enzymes, they devised a catalyst that consisted of nanoparticles of iron sulfide, which activates the nitric oxide-producing reaction in the presence of an electric field and nitrite. By further doping these nanoparticles with platinum, the team was able to enhance their electrocatalytic efficiency.

To miniaturize the electrocatalytic cell to the scale of biological cells, the team has created custom fibers containing the positive and negative microelectrodes, which are coated with the iron sulfide nanoparticles, and a microfluidic channel for the delivery of sodium nitrite, the precursor material. When implanted in the brain, these fibers direct the precursor to the specific neurons. Then the reaction can be activated at will electrochemically, through the electrodes in the same fiber, producing an instant burst of nitric oxide right at that spot so that its effects can be recorded in real-time.

Device created by the Anikeeva lab. The tube at top is connected to a supply of the precursor material, sodium nitrite, which then passes through a channel in the fiber at the bottom and into the body, which also contains the electrodes to stimulate the release of nitric oxide. The electrodes are connected through the four-pin connector on the left.
Photo: Anikeeva Lab

As a test, they used the system in a rodent model to activate a brain region that is known to be a reward center for motivation and social interaction, and that plays a role in addiction. They showed that it did indeed provoke the expected signaling responses, demonstrating its effectiveness.

Anikeeva says this “would be a very useful biological research platform, because finally, people will have a way to study the role of nitric oxide at the level of single cells, in whole organisms that are performing tasks.” She points out that there are certain disorders that are associated with disruptions of the nitric oxide signaling pathway, so more detailed studies of how this pathway operates could help lead to treatments.

The method could be generalizable, Park says, as a way of producing other molecules of biological interest within an organism. “Essentially we can now have this really scalable and miniaturized way to generate many molecules, as long as we find the appropriate catalyst, and as long as we find an appropriate starting compound that is also safe.” This approach to generating signaling molecules in situ could have wide applications in biomedicine, he says.

“One of our reviewers for this manuscript pointed out that this has never been done — electrolysis in a biological system has never been leveraged to control biological function,” Anikeeva says. “So, this is essentially the beginning of a field that could potentially be very useful” to study molecules that can be delivered at precise locations and times, for studies in neurobiology or any other biological functions. That ability to make molecules on demand inside the body could be useful in fields such as immunology or cancer research, she says.

The project got started as a result of a chance conversation between Park and Jin, who were friends working in different fields — neurobiology and electrochemistry. Their initial casual discussions ended up leading to a full-blown collaboration between several departments. But in today’s locked-down world, Jin says, such chance encounters and conversations have become less likely. “In the context of how much the world has changed, if this were in this era in which we’re all apart from each other, and not in 2018, there is some chance that this collaboration may just not ever have happened.”

“This work is a milestone in bioelectronics,” says Bozhi Tian, an associate professor of chemistry at the University of Chicago, who was not connected to this work. “It integrates nanoenabled catalysis, microfluidics, and traditional bioelectronics … and it solves a longstanding challenge of precise neuromodulation in the brain, by in situ generation of signaling molecules. This approach can be widely adopted by the neuroscience community and can be generalized to other signaling systems, too.”

Besides MIT, the team included researchers at National Chiao Tung University in Taiwan, NEC Corporation in Japan, and the Weizman Institute of Science in Israel. The work was supported by the National Institute for Neurological Disorders and Stroke, the National Institutes of Health, the National Science Foundation, and MIT’s Department of Chemical Engineering.

Researchers achieve remote control of hormone release

Abnormal levels of stress hormones such as adrenaline and cortisol are linked to a variety of mental health disorders, including depression and posttraumatic stress disorder (PTSD). MIT researchers have now devised a way to remotely control the release of these hormones from the adrenal gland, using magnetic nanoparticles.

This approach could help scientists to learn more about how hormone release influences mental health, and could eventually offer a new way to treat hormone-linked disorders, the researchers say.

“We’re looking how can we study and eventually treat stress disorders by modulating peripheral organ function, rather than doing something highly invasive in the central nervous system,” says Polina Anikeeva, an MIT professor of materials science and engineering and of brain and cognitive sciences.

To achieve control over hormone release, Dekel Rosenfeld, an MIT-Technion postdoc in Anikeeva’s group, has developed specialized magnetic nanoparticles that can be injected into the adrenal gland. When exposed to a weak magnetic field, the particles heat up slightly, activating heat-responsive channels that trigger hormone release. This technique can be used to stimulate an organ deep in the body with minimal invasiveness.

Anikeeva and Alik Widge, an assistant professor of psychiatry at the University of Minnesota and a former research fellow at MIT’s Picower Institute for Learning and Memory, are the senior authors of the study. Rosenfeld is the lead author of the paper, which appears today in Science Advances.

Controlling hormones

Anikeeva’s lab has previously devised several novel magnetic nanomaterials, including particles that can release drugs at precise times in specific locations in the body.

In the new study, the research team wanted to explore the idea of treating disorders of the brain by manipulating organs that are outside the central nervous system but influence it through hormone release. One well-known example is the hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress response in mammals. Hormones secreted by the adrenal gland, including cortisol and adrenaline, play important roles in depression, stress, and anxiety.

“Some disorders that we consider neurological may be treatable from the periphery, if we can learn to modulate those local circuits rather than going back to the global circuits in the central nervous system,” says Anikeeva, who is a member of MIT’s Research Laboratory of Electronics and McGovern Institute for Brain Research.

As a target to stimulate hormone release, the researchers decided on ion channels that control the flow of calcium into adrenal cells. Those ion channels can be activated by a variety of stimuli, including heat. When calcium flows through the open channels into adrenal cells, the cells begin pumping out hormones. “If we want to modulate the release of those hormones, we need to be able to essentially modulate the influx of calcium into adrenal cells,” Rosenfeld says.

Unlike previous research in Anikeeva’s group, in this study magnetothermal stimulation was applied to modulate the function of cells without artificially introducing any genes.

To stimulate these heat-sensitive channels, which naturally occur in adrenal cells, the researchers designed nanoparticles made of magnetite, a type of iron oxide that forms tiny magnetic crystals about 1/5000 the thickness of a human hair. In rats, they found these particles could be injected directly into the adrenal glands and remain there for at least six months. When the rats were exposed to a weak magnetic field — about 50 millitesla, 100 times weaker than the fields used for magnetic resonance imaging (MRI) — the particles heated up by about 6 degrees Celsius, enough to trigger the calcium channels to open without damaging any surrounding tissue.

The heat-sensitive channel that they targeted, known as TRPV1, is found in many sensory neurons throughout the body, including pain receptors. TRPV1 channels can be activated by capsaicin, the organic compound that gives chili peppers their heat, as well as by temperature. They are found across mammalian species, and belong to a family of many other channels that are also sensitive to heat.

This stimulation triggered a hormone rush — doubling cortisol production and boosting noradrenaline by about 25 percent. That led to a measurable increase in the animals’ heart rates.

Treating stress and pain

The researchers now plan to use this approach to study how hormone release affects PTSD and other disorders, and they say that eventually it could be adapted for treating such disorders. This method would offer a much less invasive alternative to potential treatments that involve implanting a medical device to electrically stimulate hormone release, which is not feasible in organs such as the adrenal glands that are soft and highly vascularized, the researchers say.

Another area where this strategy could hold promise is in the treatment of pain, because heat-sensitive ion channels are often found in pain receptors.

“Being able to modulate pain receptors with this technique potentially will allow us to study pain, control pain, and have some clinical applications in the future, which hopefully may offer an alternative to medications or implants for chronic pain,” Anikeeva says. With further investigation of the existence of TRPV1 in other organs, the technique can potentially be extended to other peripheral organs such as the digestive system and the pancreas.

The research was funded by the U.S. Defense Advance Research Projects Agency ElectRx Program, a Bose Research Grant, the National Institutes of Health BRAIN Initiative, and a MIT-Technion fellowship.